Recardio, Inc.
Quick facts
Phase 3 pipeline
- Dutogliptin + Filgrastim · Cardiovascular, Diabetes
Dutogliptin inhibits dipeptidyl peptidase-4 (DPP-4) to enhance incretin signaling and improve glycemic control, while filgrastim stimulates granulocyte colony-stimulating factor (G-CSF) receptors to promote bone marrow recovery and cardiac regeneration.
Phase 2 pipeline
- Filgrastim Injectable Product · Oncology
Stimulates the production of white blood cells by binding to and activating the G-CSF receptor.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Recardio, Inc.
What is Recardio, Inc.'s pipeline?
Recardio, Inc. has 1 drugs in Phase 3, 1 in Phase 2, 0 in Phase 1. Late-stage candidates include Dutogliptin + Filgrastim.
Related
- Sector hub: All tracked pharma companies